Publications

Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John O’Donnell, Joseph D. Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather,k,l Michael R. Jacobs, Krisztina M. Papp-Wallace, Focco van den Akker, Robert A. Bonomo

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

mBio. 2019 10(2): e00159-19

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

AAC Accepted Manuscript Posted Online 20 August 2018

Ram Iyer, Samir Moussa, Thomas Durand-Réville, Ruben Tommasi, Alita Miller

Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin

National Center for Biotechnology Information

S. McLeod, A. Shapiro, S. Moussa, M. Johnstone, R. McLaughlin, B. de Jonge and A. Miller

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii

Antimicrob. Agents Chemother. February 2018 vol. 62 no. 2 e01576-17

Adam B. Shapiro, Ning Gao, Haris Jahić, Nicole M. Carter, April Chen, and Alita A. Miller.

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

ACS Infectious Diseases (2017)

Durand-Réville T, et al

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Nature Microbiology (2017)